Biofrontera AG Statistics

Total Valuation

Biofrontera AG has a market cap or net worth of EUR 14.40 million. The enterprise value is 10.16 million.

Market Cap	14.40M
Enterprise Value	10.16M

Important Dates

The last earnings date was Saturday, May 31, 2025.

Earnings Date	May 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Biofrontera AG has 6.08 million shares outstanding. The number of shares has increased by 64.54% in one year.

Current Share Class	6.08M
Shares Outstanding	6.08M
Shares Change (YoY)	+64.54%
Shares Change (QoQ)	+1.43%
Owned by Insiders (%)	0.08%
Owned by Institutions (%)	7.34%
Float	1.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.61
PB Ratio	0.74
P/TBV Ratio	0.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.54
EV / Sales	0.43
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.76, with a Debt / Equity ratio of 0.03.

Current Ratio	1.76
Quick Ratio	1.07
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-439.50

Financial Efficiency

Return on equity (ROE) is -5.24% and return on invested capital (ROIC) is -11.42%.

Return on Equity (ROE)	-5.24%
Return on Assets (ROA)	-7.77%
Return on Invested Capital (ROIC)	-11.42%
Return on Capital Employed (ROCE)	-17.78%
Revenue Per Employee	272,655
Profits Per Employee	-11,080
Employee Count	88
Asset Turnover	0.84
Inventory Turnover	1.11

Taxes

Income Tax	-2.37M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.88% in the last 52 weeks. The beta is 0.12, so Biofrontera AG's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	-24.88%
50-Day Moving Average	2.49
200-Day Moving Average	2.49
Relative Strength Index (RSI)	38.53
Average Volume (20 Days)	2,085

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biofrontera AG had revenue of EUR 23.72 million and -964,000 in losses. Loss per share was -0.16.

Revenue	23.72M
Gross Profit	18.08M
Operating Income	-3.52M
Pretax Income	-3.33M
Net Income	-964,000
EBITDA	-3.27M
EBIT	-3.52M
Loss Per Share	-0.16

Full Income Statement

Balance Sheet

The company has 4.90 million in cash and 651,000 in debt, giving a net cash position of 4.25 million or 0.70 per share.

Cash & Cash Equivalents	4.90M
Total Debt	651,000
Net Cash	4.25M
Net Cash Per Share	0.70
Equity (Book Value)	19.55M
Book Value Per Share	3.22
Working Capital	6.66M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 76.21%, with operating and profit margins of -14.82% and -4.06%.

Gross Margin	76.21%
Operating Margin	-14.82%
Pretax Margin	-14.05%
Profit Margin	-4.06%
EBITDA Margin	-13.77%
EBIT Margin	-14.82%
FCF Margin	n/a

Dividends & Yields

Biofrontera AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-64.54%
Shareholder Yield	n/a
Earnings Yield	-6.69%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 14, 2024. It was a reverse split with a ratio of 0.047619.

Last Split Date	May 14, 2024
Split Type	Reverse
Split Ratio	0.047619

Scores

Biofrontera AG has an Altman Z-Score of -4.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.34
Piotroski F-Score	1